Bobak R. Azamian
President/CEO and Board Chair at Tarsus Pharmaceuticals Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Tarsus Pharmaceuticals Inc., 3 years.
Tarsus Pharmaceuticals Inc.
Director · President/CEO and Board Chair
Chief executive roles
Tarsus Pharmaceuticals Inc.
· President/CEO and Board Chair
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 17, 2026 | Tarsus Pharmaceuticals Inc. | Open-market sale | −4,582 | $61.24 | $280,602 |
| Jun 17, 2026 | Tarsus Pharmaceuticals Inc. | Open-market sale | −5,418 | $61.81 | $334,887 |
| Mar 19, 2026 | Tarsus Pharmaceuticals Inc. | Open-market sale | −11,964 | $67.00 | $801,588 |
| Mar 18, 2026 | Tarsus Pharmaceuticals Inc. | Open-market sale | −11,667 | $68.71 | $801,640 |
| Mar 17, 2026 | Tarsus Pharmaceuticals Inc. | Open-market sale | −10,972 | $69.42 | $761,676 |
| Mar 15, 2026 | Tarsus Pharmaceuticals Inc. | Option exercise | +66,274 | — | — |
| Dec 24, 2025 | Tarsus Pharmaceuticals Inc. | Open-market sale | −5,443 | $82.41 | $448,558 |
| Dec 24, 2025 | Tarsus Pharmaceuticals Inc. | Open-market sale | −557 | $83.54 | $46,532 |
| Dec 4, 2025 | Tarsus Pharmaceuticals Inc. | Gift | −51,885 | — | — |
| Sep 24, 2025 | Tarsus Pharmaceuticals Inc. | Open-market sale | −6,000 | $55.37 | $332,220 |
| Aug 11, 2025 | Tarsus Pharmaceuticals Inc. | Open-market sale | −6,000 | $50.00 | $300,000 |
| Mar 24, 2025 | Tarsus Pharmaceuticals Inc. | Open-market sale | −6,000 | $50.00 | $300,000 |
| Mar 20, 2025 | Tarsus Pharmaceuticals Inc. | Open-market sale | −8,534 | $50.11 | $427,639 |
| Mar 19, 2025 | Tarsus Pharmaceuticals Inc. | Open-market sale | −8,551 | $47.40 | $405,317 |
| Mar 18, 2025 | Tarsus Pharmaceuticals Inc. | Open-market sale | −7,131 | $46.29 | $330,094 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.